News | January 12, 2022
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
Ind-Ra expects revenue growth of over 12% in 2022.
Ind-Ra expects revenue growth of over 12% in 2022.
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Subscribe To Our Newsletter & Stay Updated
